HIMSS19: The Importance of Data and Managing Expectations

01 February, 2019

In healthcare, there is so much promise and so much opportunity for technology to deliver the best care possible – but we seem to be on a gerbil wheel of grand promises where the follow through has been well behind on the delivery.?

 
Related News
COTA’s Pecora named Executive of the Year at NJBIZ Healthcare Heroes
06.21.17
Dr. Andrew Pecora said he was honored and humbled when he received the Health Care Executive of the Year award at the NJBIZ Healthcare Heroes awards event Tuesday. Pecora, the president of physician services and chief innovation officer at Hackensack Meridian Health, was quick to recognize his colleagues in the crowd as well as the other honorees at the event. Read Full Release
COTA, IBM Watson teaming up for pilot program at Hackensack Meridian
05.10.17
Imagine waiting for your diagnosis. The doctor walks in and says, “Well, I just consulted with everyone on the planet Earth over the last 30 years to see how they took care of people like you, and then I looked at a database that precisely looked at people who have exactly what you have, and are exactly like you, and this is what I have learned in the past five minutes, and this is why I am going to recommend this treatment.” Read Full Release
COTA Collaborates with Novartis Pharmaceuticals Corporation
03.27.17
Cota Healthcare, the leading data and technology platform for value-based precision medicine, today announced the signing of a major, multi-year collaboration with Novartis Pharmaceuticals Corporation to help improve clinical and cost outcomes for breast cancer patients. As part of this agreement, which expands significantly on the previous announced collaboration entered into January 2016, teams from across Novartis Pharmaceuticals Corporation will leverage Cota's research-grade, real-world evidence, web-based analysis and visualization tools, and be supported by Cota's medical, data science, and technology experts. Utilizing the real-world evidence and technology platform supplied by Cota is expected to enable Novartis Pharmaceuticals Corporation to accelerate clinical development of new therapies for breast cancer and identify which patients will benefit most. Read Full Release